Group 1 - Zelluna ASA has issued 227,096 new shares as part of a resolution by its Board of Directors to set off an option exercise fee [1] - The new share capital of Zelluna ASA is now registered at NOK 20,454,162, divided into 20,454,162 shares, each with a par value of NOK 1 [1] Group 2 - Zelluna ASA aims to provide transformative treatments for advanced solid cancers through innovative "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies [2] - The TCR-NK platform is designed to offer broad cancer detection capabilities, addressing the diversity of tumors and overcoming scaling limitations of current cell therapies [2] - The lead program targets MAGE-A4 and is the world's first "off the shelf" TCR-NK therapy for various solid cancers, with additional products in the pipeline [2] - The management team consists of biotech entrepreneurs with extensive experience in the discovery and clinical development of TCR and cell-based therapies [2]
ZLNA – New registered share capital
Globenewswire·2025-05-27 11:38